Impact News +++ Skanska divests the elderly care home Villa Fågelsång in Sollentuna, Sweden, for about SEK 340M (Cision) +++ SKANSKA Aktie -4,82%

INTELLIA Aktie

>INTELLIA Aktienkurs

11.153 EUR (TradegateBSX)

Ask: 11.25 EUR / 535 Stück

Bid: 11.055 EUR / 272 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INTELLIA Aktie über LYNX handeln

Intraday

1 Jahr

>INTELLIA Performance

1 Woche: +2,0%

1 Monat: -14,6%

3 Monate: +43,5%

6 Monate: -24,9%

1 Jahr: +69,8%

laufendes Jahr: +43,5%

>INTELLIA Aktie

Name:

INTELLIA THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45826J1051 / A2AG6H

Symbol/ Ticker:

38I (Frankfurt) / NTLA (NASDAQ)

Kürzel:

FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA

Index:

Webseite:

https://www.intelliatx.co..

Profil:

Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative treatments using CRISPR/Cas9 technology. The company transforms medicine by permanently editing and correcting disease-associated genes within the human b..
>Volltext..

Marktkapitalisierung:

1189.95 Mio. EUR

Unternehmenswert:

889.07 Mio. EUR

Umsatz:

58.51 Mio. EUR

EBITDA:

-361.88 Mio. EUR

Nettogewinn:

-356.83 Mio. EUR

Gewinn je Aktie:

-3.31 EUR

Schulden:

80.69 Mio. EUR

Liquide Mittel:

134.42 Mio. EUR

Operativer Cashflow:

-341.3 Mio. EUR

Bargeldquote:

4.33

Umsatzwachstum:

3.06%

Gewinnwachstum:

29.92%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 25.052 USD.

Suchwörter:

INTELLIA

Letzte Datenerhebung:

01.04.26

>INTELLIA Kennzahlen

Aktien/ Unternehmen:

Aktien: 118.13 Mio. St.

Frei handelbar: 94.88%

Leerverk. Aktien: 33.39%

Rückkaufquote: -9.55%

Mitarbeiter: 377

Umsatz/Mitarb.: 0.16 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 94.79%

Bewertung:

KGV: -

KGV lG: -

KUV: 20.94

KBV: 2.27

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 76.43%

Gewinnmarge: -609.85%

Operative Marge: -642.06%

Managementeffizenz:

Gesamtkaprendite: -40.6%

Eigenkaprendite: -53.48%

>INTELLIA Peer Group

Gesundheit, Autoimmunerkrankungen, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>INTELLIA Chart & Kurs - NASDAQ

>INTELLIA News

09.03.26 - 15:42	Intellia Therapeutics auf der Leerink-Konferenz: Gen-Editing-Therapie Lonbo-Z mit hohem Margenpotenzial (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.03.26 - 22:03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on March 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment....

04.03.26 - 13:57	This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday (Benzinga)
	Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Potential to buy TGT stock, analysts say. Photo via Shutterstock Importance Rank: 1 read more...

04.03.26 - 06:06	Intellia Therapeutics auf der TD Cowen Konferenz: Strategische Fortschritte und Herausforderungen (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.03.26 - 05:02	Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 8364 USD (Insiderkauf)
	Clark, Eliana - Vorstand - Tag der Transaktion: 2026-03-02...

04.03.26 - 05:02	Insiderhandel: EVP, General Counsel verkauft Aktien von Intellia Therapeutics im Wert von 16688 USD (Insiderkauf)
	Basta, James - Vorstand - Tag der Transaktion: 2026-03-02...

03.03.26 - 13:33

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 (GlobeNewswire EN)

Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients' continued treatment burden and unmet needs Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients' continued treatment burden and unmet needs...

02.03.26 - 14:31	Intellia-Aktie legt nach FDA-Entscheidung zu: Klinische Sperre für Gentherapie aufgehoben (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.03.26 - 13:33

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM (GlobeNewswire EN)

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)....

27.02.26 - 03:51	Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 21:01	Intellia (NTLA) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 19:45	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +15.82% and +94.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

26.02.26 - 13:33	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire EN)
	CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the fourth quarter and year ended December 31, 2025....

25.02.26 - 15:54	Intellia Therapeutics Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 16:00	Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus (Zacks)
	NTLA, CL and GTY are in focus as Zacks highlights strong 12-week gains and post-upgrade rallies across its Focus List and model portfolios....

19.02.26 - 13:33	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (GlobeNewswire EN)
	CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates....

06.02.26 - 13:33	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment....

30.01.26 - 19:01	Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea′s APR-1051 Paces; CALC Halts KOURAGE (AFX)
	SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeu......

28.01.26 - 15:15	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
	Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....

27.01.26 - 14:36	Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es gibt einen Tag, um geboren zu werden, und einen Tag, um zu sterben. - China Weisheit

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram